Valiant Laboratories Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 420.8% YoY, showing strong momentum
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.83x)
- Working capital cycle has improved - days down from 367 to 269
- Company generates healthy free cash flow
- Company maintains a comfortable, low leverage position
CONS
- Company is loss-making at the operating / net level
- Operating cash flow has been negative in recent years
- Receivables are growing faster than sales - a possible quality concern
- Interest coverage is weak at -7.3x - earnings barely cover interest
- Company has a low return on capital employed of 8.5%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.00 | 37.67 | 455633.71 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9100.00 | 82.59 | 241576.41 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4850.00 | 84.58 | 184478.41 | 0.78 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| CIPLA | 1385.00 | 33.19 | 111888.39 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| ZYDUSLIFE | 1121.00 | 24.78 | 111820.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| LAURUSLABS | 1840.00 | 90.93 | 99417.45 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2111.00 | 17.46 | 96528.82 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1154.00 | 29.89 | 96322.06 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2328.55 | 47.09 | 96179.61 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| AUROPHARMA | 1653.30 | 25.62 | 95127.23 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2427.00 | 38.10 | 68495.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| VALIANTLAB | 107.27 | 36.40 | 582.61 | 0.00 | 21.10 | 1058.87 | 115.28 | 146.23 | -0.40 | 25.38 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51 | 60 | 41 | 31 | 19 | 21 | 35 | 58 | 51 | 46 | 55 | 65 | 73 | |
| 48 | 61 | 47 | 35 | 21 | 28 | 35 | 54 | 49 | 46 | 54 | 61 | 62 | |
| Operating Profit | 4 | -1 | -6 | -5 | -2 | -7 | 1 | 4 | 2 | 0 | 0 | 4 | 12 |
| OPM % | 7.43% | -2.32% | -15.55% | -14.81% | -12.66% | -31.38% | 1.76% | 6.63% | 4.63% | 0.13% | 0.46% | 6.89% | 16.17% |
| 2 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before Tax | 6 | 1 | -5 | -3 | -1 | -5 | 1 | 4 | 2 | 0 | 0 | 5 | 13 |
| Tax % | 26.12% | 25.47% | 30.50% | 52.16% | -29.87% | -12.41% | -122.22% | 17.60% | 25.71% | 34.62% | 72.73% | 25.32% | 25.53% |
| Net Profit | 4 | 1 | -4 | -1 | -1 | -6 | 2 | 3 | 2 | 0 | 0 | 4 | 9 |
| 1.31 | 0.24 | -0.81 | -0.32 | -0.23 | -1.39 | 0.37 | 0.74 | 0.42 | 0.03 | 0.01 | 0.65 | 1.75 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 292 | 334 | 182 | 133 | 239 | |
| 249 | 299 | 190 | 138 | 223 | |
| Operating Profit | 42 | 35 | -8 | -5 | 17 |
| OPM % | 14.52% | 10.50% | -4.62% | -3.52% | 6.97% |
| 2 | 5 | 10 | 5 | 3 | |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 |
| Profit before Tax | 42 | 38 | -1 | -1 | 18 |
| Tax % | 34.07% | 23.96% | 145.22% | -48.51% | 25.89% |
| Net Profit | 27 | 29 | 0 | -2 | 13 |
| EPS | 9.52 | 8.91 | 0.08 | -0.49 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- -23%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 23%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 11%
- Last Year:
- -1%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 16 | 33 | 43 | 43 |
| 55 | 68 | 193 | 191 | |
| 62 | 61 | 61 | 61 | |
| Trade Payables | 46 | 47 | 25 | 19 |
| 2 | 4 | 2 | 3 | |
| Total Liabilities | 182 | 213 | 325 | 317 |
| 22 | 30 | 32 | 30 | |
| Capital Work in Progress | 1 | 0 | 0 | 0 |
| 0 | 34 | 119 | 165 | |
| 16 | 13 | 10 | 4 | |
| 0 | 0 | 46 | 72 | |
| Cash & Bank | 20 | 0 | 97 | 27 |
| 122 | 135 | 22 | 19 | |
| Total Assets | 182 | 213 | 325 | 317 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 17 | 32 | 49 | -22 | |
| Cash from Investing | -12 | -21 | -183 | 25 |
| Cash from Financing | 6 | -2 | 136 | -1 |
| -4 | 0 | 2 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| PER SHARE | ||||
| EPS (₹) | 16.89 | 8.91 | 0.08 | -0.49 |
| Book Value (₹) | 43.89 | 30.86 | 54.52 | 53.94 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 8.55 | 8.71 | 0.49 | -0.03 |
| PROFITABILITY | ||||
| Operating Margin % | 15.18% | 11.97% | -4.62% | -3.52% |
| Net Margin % | 9.43% | 8.68% | 0.19% | -1.61% |
| ROE % | 38.48% | 33.73% | 0.20% | -0.91% |
| ROCE % | 31.62% | 26.29% | -0.30% | -0.43% |
| 15.12% | 14.70% | 0.13% | -0.67% | |
| EFFICIENCY | ||||
| Debtor Days | 139 | 109 | 135 | 161 |
| Inventory Days | 20 | 16 | 23 | 19 |
| Payable Days | 72 | 62 | 79 | 69 |
| 86 | 63 | 79 | 111 | |
| FINANCIAL HEALTH | ||||
| Debt to Equity (x) | 0.85x | 0.59x | 0.25x | 0.25x |
| Interest Coverage (x) | 572.29x | 151.32x | -8.67x | -7.26x |
| 3.17x | 3.60x | 7.94x | 5.69x | |
| GROWTH | ||||
| Revenue Growth % | 0.00% | 14.54% | -45.48% | -26.75% |
| Operating Profit Growth % | 0.00% | -9.74% | -96.81% | -40.94% |
| Net Profit Growth % | 0.00% | 5.46% | -98.83% | -731.85% |
| 0.00% | 0.00% | -99.12% | -731.85% | |
| VALUATION | ||||
| P/E (x) | 0.00x | 0.00x | 1725.47x | 0.00x |
| P/B (x) | 0.00x | 0.00x | 2.67x | 1.42x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 467.50x | 486.26x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-04 - Valiant Laboratories Limited has informed the Exchange regarding Dispatch of Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to the members of the Company.
2026-09-03 - Valiant Laboratories Limited has informed the Exchange about Credit Rating
2026-09-03 - Valiant Laboratories Limited has informed the Exchange 'Letter to shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations 2015'.
2026-09-03 - Valiant Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026 and the Annual Report for the FY 2025-26
2026-08-31 - Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. 5th AGM of the Company
2026-08-12 - Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-10 - Monitoring Agency Report for quarter ended June 30, 2026
2026-08-10 - Valiant Laboratories Limited has informed the Exchange regarding change in Corporate Office of the company.
2026-08-10 - Valiant Laboratories Limited has informed the Exchange regarding change in Registered Office of the company.
News
Recent coverage and analyst commentary for VALIANTLAB
Loading news…
AI Stock Analyst
Valiant Laboratories Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account